Article
Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials.
Oncology research and treatment - 1 Jan 2021
Yin Qifan, Xun Xuejiao, Yang Guang, Cui Hongshang, Liu Huining
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have recently become the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. This study aimed to define the role of EGFR-TKI treatment in the adjuvant setting of patients with resected EGFR-mutant NSCLC. METHODS: Three online databases (PubMed, Embase, and the Cochrane...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.